{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:41:21Z","timestamp":1717540881164},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ejca.2011.08.015","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T22:21:27Z","timestamp":1317248487000},"page":"233-236","source":"Crossref","is-referenced-by-count":17,"title":["Quantitative monitoring of BCR\/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia"],"prefix":"10.1016","volume":"48","author":[{"given":"S.","family":"Preuner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mitterbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mannhalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Herndlhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.08.015_b0005","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.08.015_b0010","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.08.015_b0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.08.015_b0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/asheducation-2007.1.376","article-title":"Chronic myeloid leukemia: molecular monitoring in clinical practice","author":"Branford","year":"2007","journal-title":"Hematol Am Soc Hematol Edu Program"},{"key":"10.1016\/j.ejca.2011.08.015_b0025","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2011.08.015_b0030","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0035","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.08.015_b0040","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.08.015_b0045","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0050","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3109\/10428191003729741","article-title":"Mutations in ABL kinase domain are associated with inferior progression-free survival","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2011.08.015_b0055","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0060","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2011.08.015_b0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Khorashad","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.08.015_b0070","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2008-10-183665","article-title":"BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib","volume":"116","author":"Sherbenou","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/j.seminhematol.2010.06.007","article-title":"Practical considerations for monitoring patients with chronic myeloid leukemia","volume":"47","author":"Branford","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ejca.2011.08.015_b0080","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0085","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2008.97","article-title":"Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR)","volume":"22","author":"Preuner","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2011.08.015_b0090","first-page":"93","article-title":"Detection of BCR-ABL mutations and resistance to imatinib mesylate","volume":"125","author":"Branford","year":"2006","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ejca.2011.08.015_b0095","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2011.08.015_b0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ejca.2011.08.015_b0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2010.03.002","article-title":"Cancer stem cells: back to Darwin?","volume":"20","author":"Greaves","year":"2010","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.ejca.2011.08.015_b0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature09733","article-title":"Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells","volume":"469","author":"Notta","year":"2011","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911006411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911006411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T20:56:55Z","timestamp":1543525015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911006411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0959804911006411"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.08.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}